Its ability to be delivered through multiple routes may stem from a possible affinity for a peptide transporter, hPepT1, that occurs in the gastrointestinal tract.3 Researchers have also administered KPV topically or transdermally through technologies such as ionophoresis, which uses small electrical currents to drive the medication through the skin.4 There are even battery-integrated patches that use this technology.5 That being said, subcutaneous injection is likely the most rapid form of KPV drug delivery for systemic benefits, as well as the form you have the best chances of getting for your own use
Fluid retention, joint discomfort, headache Mild edema, joint stiffness, and headaches are commonly reported in the IGF-1 pathway literature, including IGF-1 LR3 community reports
Safety and Risk Management Safety assessment Although animal experiments have shown that BPC 157 has good tolerance, its safety in humans has not been fully verified
The harder truth is that this isnt just tolerance
But the sheer volume of rodent studies (over 100 at this point) paints a remarkably consistent picture, and the anecdotal reports from bodybuilders and athletes line up pretty closely with what the science predicts
